Vaccine Platform  Type of Vaccine and Immunogen  Developer(Name of Vaccine)  Dose Scheduleand Administration  Phase*  Excipients†
RNA-based vaccine  mRNA encoding spike protein (30 μg)  BioNTech–Pfizer(BNT162b2)  Two doses (day 0, day 21)
Intramuscular  Post-EUA  0.43 mg ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.2 mg cholesterol, 0.01 mg potassium chloride, 0.01 mg monobasic potassium phosphate, 0.36 mg sodium chloride, 0.07 mg dibasic sodium phosphate dihydrate, and 6 mg sucrose. The diluent (0.9% sodium chloride Injection) contributes an additional 2.16 mg sodium chloride per dose
RNA-based vaccine  mRNA encoding spike protein (100 μg)  Moderna(mRNA-1273)  Two doses (day 0, day 28)
Intramuscular  Post-EUA  Lipids (SM-102; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 [PEG 2000-DMG]; cholesterol; and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose
Adenovirus vector (nonreplicating)  ChAdOx1-Sn Cov-19
Nonreplicating chimpanzee AdV5 expressing spike protein  AstraZeneca and University of Oxford(AZD1222)  One (day 0) or two (day 0, day 28) doses
Intramuscular  Phase 3  10 mM histidine, 7.5% (w/v) sucrose,35 mM sodium chloride, 1 mM magnesiumchloride, 0.1% (w/v) polysorbate 80,0.1 mM edetate disodium, 0.5% (w/v)ethanol, at pH 6.6
Adenovirus vector(nonreplicating)  Ad26.COV2.S
Adenovirus 26 vectored vaccine using AdVac and PER.C6 technology  Janssen  One (day 0) or two (day 0, day 56) doses
Intramuscular  Phase 3  Sodium chloride, citric acid monohydrate, polysorbate 80, 2 hydroxypropyl-B-cyclodextrin (HBCD), ethanol (absolute), sodium hydroxide
Protein subunit  Full-length recombinant SARS-CoV-2 glycoprotein nanoparticle with Matrix M adjuvant
Spike prefusion protein  Novavax  Two doses (day 0, day 21)
Intramuscular  Phase 3  Matrix M1 adjuvantFull-length spike protein formulated in polysorbate 80 detergent and Matrix M1 adjuvant
Protein subunit  SARS-CoV-2 vaccine formulation with adjuvant (S-protein) (Baculovirus production)
Spike protein  Sanofi Pasteur and GSK  Two doses (day 0, day 21)
Intramuscular  Phase 1–2  Sodium phosphate monobasic monohydrate, sodium phosphate dibasic, sodium chloride polysorbate 20, disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride